565 related articles for article (PubMed ID: 18236404)
21. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2013 May; 57(1):50-3. PubMed ID: 23403239
[TBL] [Abstract][Full Text] [Related]
22. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.
Scott GM; Naing Z; Pavlovic J; Iwasenko JM; Angus P; Jones R; Rawlinson WD
J Clin Virol; 2011 Aug; 51(4):229-33. PubMed ID: 21641274
[TBL] [Abstract][Full Text] [Related]
23. Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.
Luna E; Caravaca F; Ferreira F; Fernandez N; Martín P; Vargas ML; Saenz de Santamaría J; Garcia Pino G; Azevedo L; Muñoz Sanz A
Transplant Proc; 2016 Nov; 48(9):2931-2937. PubMed ID: 27932110
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
[TBL] [Abstract][Full Text] [Related]
25. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
27. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
Khoury JA; Storch GA; Bohl DL; Schuessler RM; Torrence SM; Lockwood M; Gaudreault-Keener M; Koch MJ; Miller BW; Hardinger KL; Schnitzler MA; Brennan DC
Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
[TBL] [Abstract][Full Text] [Related]
29. Preemptive therapy in CMV-antigen positive patients after liver transplantation--a prospective trial.
Rayes N; Oettle H; Schmidt CA; Lohmann R; Steinmüller T; Bechstein WO; Neuhaus P
Ann Transplant; 1999; 4(2):12-7. PubMed ID: 10850585
[TBL] [Abstract][Full Text] [Related]
30. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
31. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
33. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
[TBL] [Abstract][Full Text] [Related]
34. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.
Saitoh A; Sakamoto S; Fukuda A; Shigeta T; Kakiuchi T; Kamiyama S; Katsuta T; Shoji K; Ogimi C; Kasahara M
Transplantation; 2011 Oct; 92(8):930-5. PubMed ID: 21941226
[TBL] [Abstract][Full Text] [Related]
35. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
36. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
37. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
Díaz-Pedroche C; Lumbreras C; San Juan R; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno-Elola A; Hernando S; Moreno-González E; Aguado JM
Transplantation; 2006 Jul; 82(1):30-5. PubMed ID: 16861938
[TBL] [Abstract][Full Text] [Related]
38. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
[TBL] [Abstract][Full Text] [Related]
39. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
